Clicky

Eli Lilly and Company(LILY34)

Description: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.


Keywords: Biotechnology Biopharmaceutical Life Sciences Drugs Pain Diabetes Breast Cancer Rheumatoid Arthritis Non Small Cell Lung Cancer Colorectal Cancer Osteoporosis Schizophrenia Insulin Migraine Erectile Dysfunction Hepatocellular Carcinoma Head And Neck Cancer Fibromyalgia Psoriatic Arthritis Nsclc Benign Prostatic Hyperplasia Plaque Psoriasis Metastatic Colorectal Cancer Spondylitis Hodgkin Thyroid Cancer Depressive Disorder Boehringer Ingelheim Anxiety Disorder Malignant Pleural Mesothelioma Migraine Prevention Medullary Thyroid Cancer Cialis Cyramza Insulin Lispro Metastatic Gastric Cancer Cymbalta Pemetrexed Ramucirumab Alimta Annual Pharmaceutical Drug Sales Basaglar Chronic Musculoskeletal Pain Episodic Cluster Headache Erbitux Forteo Gastro Esophageal Junction Adenocarcinoma Her2 Metastatic Breast Cancer Humalog Humulin 70/30 Humulin N Markets Human Pharmaceuticals Non Radiographic Axial Spondylarthritis Trajenta Zyprexa

Home Page: www.lilly.com

Lilly Corporate Center
Indianapolis, IN 46285
United States
Phone: 317 276 2000


Officers

Name Title
Mr. David A. Ricks Chairman, CEO & Pres
Ms. Anat Ashkenazi Sr. VP & CFO
Dr. Daniel M. Skovronsky M.D., Ph.D. Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs
Mr. Diogo Rau Sr. VP & Chief Information and Digital Officer
Mr. Jacob S. Van Naarden Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology
Mr. Donald A. Zakrowski Chief Accounting Officer & VP of Fin.
Mr. Martin Bott MIBS VP of Fin. & Special Projects
Ms. Anat Hakim J.D. Sr. VP, Gen. Counsel & Sec.
Mr. Alonzo Weems Sr. VP and Chief Ethics & Compliance Officer
Ms. Leigh Ann Pusey Sr. VP of Corp. Affairs & Communications

Exchange: SA

Country: BR : Brazil

Currency: Brazilian real (R$)

Forward PE: 39.3701
Trailing PE: 53.2
Price-to-Book MRQ: 34.1322
Price-to-Sales TTM: 60.9306
IPO Date:
Fiscal Year End: December
Full Time Employees: 35000
Back to stocks